ESCRS - Mobile patient bed ;
ESCRS - Mobile patient bed ;

Mobile patient bed

Mobile patient bed
Colin Kerr
Colin Kerr
Published: Wednesday, November 1, 2017
Johnson & Johnson Vision’s CATALYS System Mobile Patient Bed has received FDA clearance for sale in the United States and will be available for sale this month. “Our goal with this innovation is to enhance patients’ overall surgical experience, so we worked to provide an easy transition as they move from one part of their cataract procedure to the next and premium comfort while they are in the operating room,” said Tom Frinzi, Worldwide President, Surgical Vision, at Johnson & Johnson Vision. “We also designed the mobility and adaptability features of this bed to help simplify the workflow for surgeons between the laser cataract suite and phacoemulsification.” www.jnjvision.com
Tags: patient care
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Piecing Together a Solution

What is the best use of robotics and AI in cataract and refractive surgery?

Read more...

Advances in Toric IOL Alignment

Biomorphometric approaches offer high precision and increase efficiency.

Read more...

Library of Short Videos Complements Educational Offerings

Read more...

Tackling Waste in Retinal Surgery

Reducing waste from intravitreal injections is an achievable goal.

Read more...

The Modern Era of Refractive Surgery

New technologies for screening and treatment qualify more patients for intervention.

Read more...

Monofocal Plus Finding the Balance

Enhanced monofocals may be the future standard of care in cataract patients.

Read more...

Growing Options Optimise Outcomes in Cataract Surgery

Understanding the promise and potential problems of AI-based IOL formulas.

Read more...

;